碱基切除修复及其靶向治疗策略

doi:10.3760/cma.j.issn.1673-422X.2017.11.013

摘要/Abstract

摘要： 碱基切除修复（BER）是DNA氧化损伤修复的重要通路，该通路的突变造成基因不稳定而增加癌症风险。大量研究已证明，BER通路的关键蛋白，如DNA糖基化酶、脱嘌呤/嘧啶核酸内切酶1、DNA聚合酶等，在多种肿瘤中异常表达。此外这些蛋白的单核苷酸多态性影响肿瘤细胞的修复活性，有望成为肿瘤诊断、治疗及预后评估的重要指标。

关键词: 基因修复, 多态性, 基因组不稳定性, 碱基切除修复

Abstract: Base excision repair (BER) is an important pathway for DNA oxidative damage repair, and mutations in this pathway cause gene instability and increase cancer risk. A large number of studies have shown that abnormal expression of key proteins in the BER pathway in a variety of tumors, such as DNA glycosylase, apurinic/apyrimidinic endonuclease 1, DNA polymerase and so on. Single nucleotide polymorphisms of these proteins affect the repair activity of tumor cells, and are expected to be important indicators for the diagnosis, treatment and evaluation of prognosis.

Key words: DNA repair, Polymorphism, Genomic instability, Base excision repair

张天棋，王红兵. 碱基切除修复及其靶向治疗策略[J]. 国际肿瘤学杂志, 2017, 44(11): 856-859.

张天棋，王红兵. Base excision repair and targeted therapy strategies[J]. Journal of International Oncology, 2017, 44(11): 856-859.

参考文献

［1］ Dutta A, Yang C, Sengupta S, et al. New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins［J］. Cell Mol Life Sci, 2015, 72(9): 1679-1698. DOI: 10.1007/s00018-014-1820-z. ［2］ Abbotts R, Wilson DM 3rd. Coordination of DNA single strand break repair［J］. Free Radic Biol Med, 2017, 107: 228-244. DOI: 10.1016/j.freeradbiomed.2016.11.039. ［3］ Bharti SK, Brosh RM. Finetuning DNA repair by protein acetylation［J］. Cell Cycle, 2016, 15(15): 1952-1953. DOI: 10.1080/15384101.2016.1191250. ［4］ Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety［J］. Ann Oncol, 2016, 27(6): 1013-1019. DOI: 10.1093/annonc/mdw133. ［5］ Gavande NS, VandervereCarozza PS, Hinshaw HD, et al. DNA repair targeted therapy: the past or future of cancer treatment?［J］. Pharmacol Ther, 2016, 160: 65-83. DOI: 10.1016/j.pharmthera.2016.02.003. ［6］ Mateo J, Carreira S, Sandhu S, et al. DNArepair defects and olaparib in metastatic prostate cancer［J］. N Engl J Med, 2015, 373(18): 1697-1708. DOI: 10.1056/NEJMoa1506859. ［7］ Mccrudden CM, O′rourke MG, Cherry KE, et al. Vasoactivity of rucaparib, a PARP1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself［J］. PLoS One, 2015, 10(2): e0118187. DOI: 10.1371/journal.pone.0118187. ［8］ Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADPribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer［J］. Br J Cancer, 2016, 114(7): 723730. DOI: 10.1038/bjc.2016.41. ［9］ Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinumsensitive, recurrent ovarian cancer［J］. N Engl J Med, 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310. ［10］ Engert F, Kovac M, Baumhoer D, et al. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics［J］. Oncotarget, 2017, 8(30): 48794-48806. DOI: 10.18632/oncotarget.10720. ［11］ Kim Y, Kim A, Sharip A, et al. Reverse the resistance to PARP inhibitors［J］. Int J Biol Sci, 2017, 13(2): 198-208. DOI: 10.7150/ijbs.17240. ［12］ Laev SS, Salakhutdinov NF, Lavrik OI. Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref1)［J］. Bioorg Med Chem, 2017, 25(9): 2531-2544. DOI: 10.1016/j.bmc.2017.01.028. ［13］ Tell G, Fantini D, Quadrifoglio F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment［J］. Cell Mol Life Sci, 2010, 67(21): 3589-3608. DOI: 10.1007/s00018-010-0486-4. ［14］崔熠, 金孝华, 胡玮. 大豆异黄酮对乳腺癌细胞抑癌基因启动子区的去甲基化作用研究［J］. 中国计划生育学杂志, 2014, 22(6): 381-385. DOI: 10.3969/j.issn.1004-8189.2014.06. ［15］王东. 基于DNA损伤修复的分子靶向治疗: 肿瘤靶向治疗的新篇章［J］. 第三军医大学学报, 2014, 36(22): 22432248. ［16］ He LF, Luo L, Zhu H, et al.FEN1 promotes tumor progression and confers cisplatin resistance in NSCLC［J］. Mol Oncol, 2017, 11(6): 640-654. DOI: 10.1002/1878-0261.12058. ［17］ Zhou T, Pan F, Cao Y, et al. R152C DNA pol β mutation impairs base excision repair and induces cellular transformation［J］. Oncotarget, 2016, 7(6): 6902-6915. DOI: 10.18632/oncotarget.6849. ［18］ Nemec AA, Donigan KA, Murphy DL, et al. Colon cancerassociated DNA polymerase β variant induces genomic instability and cellular transformation［J］. J Biol Chem, 2012, 287(28): 23840-23849. DOI: 10.1074/jbc.M112.362111. ［19］ Jaiswal AS, Banerjee S, Aneja R, et al. DNA polymerase-β as a novel target for chemotherapeutic intervention of colorectal cancer［J］. PLoS One, 2011, 6(2): e16691. DOI: 10.1371/journal.pone.0016691. ［20］ Capp JP, Boudsocq F, Bergoglio V, et al. The R438W polymorphism of human DNA polymerase lambda triggers cellular sensitivity to camptothecin by compromising the homologous recombination repair pathway［J］. Carcinogenesis, 2010, 31(10): 17421747. DOI: 10.1093/carcin/bgq166. ［21］ Mentegari E, Kissova M, Bavagnoli L, et al. DNA polymerases λ and β: the doubleedged swords of DNA repair［J］. Genes (Basel), 2016, 7(9): 57. DOI: 10.3390/genes7090057. ［22］ Gao XR, Zhang SL, Yang YF, et al. FEN1 69G>A and 4150G>T polymorphisms and cancer risk in Chinese population［J］. Sci Rep, 2014, 4: 6183. DOI: 10.1038/srep06183. ［23］ He L, Zhang Y, Sun H, et al. Targeting DNA flap endonuclease 1 to impede breast cancer progression［J］. EBioMedicine, 2016, 14: 3243. DOI: 10.1016/j.ebiom.2016.11.012. ［24］ TalsethPalme BA.The genetic basis of colonic adenomatous polyposis syndromes［J］. Hered Cancer Clin Pract, 2017, 15: 5. DOI: 10.1186/s130530170065x. ［25］马俊, 侯小强, 郑秋生, 等. DNA修复酶基因NEIL1的AI RNA编辑水平在白血病和乳腺癌细胞中的下调［J］. 军事医学, 2014, 38(6): 458462. DOI: 10.7644/j.issn.1674-9960.2014.06.013. ［26］ Dizdaroglu M, Coskun E, Jaruga P. Repair of oxidatively induced DNA damage by DNA glycosylases: mechanisms of action, substrate specificities and excision kinetics［J］. Mutat Res, 2017, 771: 99-127. DOI: 10.1016/j.mrrev.2017.02.001. ［27］付婷, 秦立强, 潘旭东, 等. XRCC1基因多态性与晚期非小细胞肺癌铂类化疗敏感性关系的Meta分析［J］. 江苏医药, 2015, 41(12): 14011403. ［28］ Sanjari Moghaddam A, Nazarzadeh M, Noroozi R, et al. XRCC1 and OGG1 gene polymorphisms and breast cancer: a systematic review of literature［J］. Iran J Cancer Prev, 2016, 9(1): e3467. DOI: 10.17795/ijcp-3467.

[1]	张惠博, 杨琰英, 宋启斌. MTHFR基因多态性与结直肠癌的相关性[J]. 国际肿瘤学杂志, 2017, 44(8): 619-621.
[2]	陈志鹏,卢玮冬,左云,朱陵君,宋宇,周芳,张永芹. APC基因3′-非编码区rs1804197多态性与结直肠癌易感性的关系[J]. 国际肿瘤学杂志, 2017, 44(6): 433-.
[3]	崔静,谭辉,姜雷,袁文臻,关泉林. XPC Lys939Gln(A/C)基因多态性与胃癌易感性的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(8): 597-602.
[4]	李涛, 赖春凤, 丘波, 邹浩元, 杨宇辉. CYP2E1基因多态性与客家人群胃癌易感性的研究[J]. 国际肿瘤学杂志, 2016, 43(7): 495-498.
[5]	李力宏，白仲添，胡进静，周文策. 分泌型卷曲相关蛋白家族在肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2016, 43(6): 448-451.
[6]	崔静,谭辉,姜雷,袁文臻,关泉林. XPC基因rs2228000(C/T)多态性与乳腺癌易感性的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(10): 752-757.
[7]	田源,单泽志,彭佳远,汪昱. ERCC1基因多态性在胃癌中的研究[J]. 国际肿瘤学杂志, 2014, 41(8): 666-668.
[8]	付萍,王伏霞,崔立献,崔斌,刘杰. SMAD7基因多态性与非小细胞肺癌易感性的相关性研究[J]. 国际肿瘤学杂志, 2014, 41(5): 383-386.
[9]	邓成辉, 关泉林, 姜雷, 李小奇, 甘亮亮, 魏孔孔. GSTP1 Ile105Val(A/G)多态性与进展期胃癌铂类药物化疗敏感性的Meta分析[J]. 国际肿瘤学杂志, 2014, 41(4): 309-314.
[10]	赵娜, 杨锡贵, 曹殿凤, 高萍, 张宝玲. 人类白细胞抗原HLA-DQA1基因多态性在尘肺肺癌患者中的表达[J]. 国际肿瘤学杂志, 2014, 41(10): 779-781.
[11]	钱莹莹, 束永前. 核苷酸切除修复通路基因多态性与肺癌易感性[J]. 国际肿瘤学杂志, 2013, 40(2): 126-130.
[12]	梁宁, 乔丽丽, 谢健, 张建东. NOD2基因与原发性肝癌[J]. 国际肿瘤学杂志, 2013, 40(12): 927-929.
[13]	邹喜. 细胞周期蛋白D1基因G870A 多态性与结直肠癌易感性的系统评价[J]. 国际肿瘤学杂志, 2012, 39(5): 395-400.
[14]	苏彤, 史力, 魏盖杰, 陈静. 基质金属蛋白酶9基因多态性与肿瘤易感性Meta分析[J]. 国际肿瘤学杂志, 2012, 39(12): 945-949.
[15]	孙姗姗, 姜永冬, 庞达. FGFR2基因多态性与乳腺癌相关性[J]. 国际肿瘤学杂志, 2011, 38(5): 361-363.